Arcturus Therapeutics’ (ARCT) Buy Rating Reiterated at HC Wainwright

Arcturus Therapeutics (NASDAQ:ARCT)‘s stock had its “buy” rating restated by research analysts at HC Wainwright in a research report issued on Friday,Benzinga reports. They presently have a $63.00 price target on the biotechnology company’s stock. HC Wainwright’s price target would suggest a potential upside of 254.33% from the company’s current price.

A number of other equities research analysts also recently weighed in on the company. BTIG Research started coverage on Arcturus Therapeutics in a report on Tuesday, January 28th. They set a “buy” rating and a $41.00 target price for the company. Cantor Fitzgerald reiterated an “overweight” rating on shares of Arcturus Therapeutics in a research note on Monday, December 16th. Six equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, Arcturus Therapeutics currently has a consensus rating of “Buy” and an average target price of $65.00.

Arcturus Therapeutics Stock Performance

Shares of NASDAQ ARCT traded up $1.37 during trading hours on Friday, reaching $17.78. 464,138 shares of the stock were exchanged, compared to its average volume of 402,919. The stock’s fifty day simple moving average is $17.06 and its 200 day simple moving average is $19.04. The firm has a market capitalization of $481.66 million, a price-to-earnings ratio of -8.01 and a beta of 2.62. Arcturus Therapeutics has a 52 week low of $14.30 and a 52 week high of $45.00.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the stock. nVerses Capital LLC acquired a new stake in Arcturus Therapeutics during the third quarter worth about $42,000. KLP Kapitalforvaltning AS acquired a new position in shares of Arcturus Therapeutics in the 4th quarter valued at approximately $71,000. National Bank of Canada FI lifted its holdings in shares of Arcturus Therapeutics by 639.6% during the 4th quarter. National Bank of Canada FI now owns 5,532 shares of the biotechnology company’s stock worth $94,000 after acquiring an additional 4,784 shares during the period. China Universal Asset Management Co. Ltd. boosted its position in shares of Arcturus Therapeutics by 64.4% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 5,201 shares of the biotechnology company’s stock worth $121,000 after acquiring an additional 2,038 shares in the last quarter. Finally, Kennedy Capital Management LLC increased its stake in Arcturus Therapeutics by 22.7% in the fourth quarter. Kennedy Capital Management LLC now owns 10,987 shares of the biotechnology company’s stock valued at $186,000 after acquiring an additional 2,036 shares during the last quarter. Institutional investors own 94.54% of the company’s stock.

About Arcturus Therapeutics

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.